FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1854164300> ?p ?o ?g. }

• W1854164300 endingPage "428" @default.
• W1854164300 startingPage "422" @default.
• W1854164300 abstract "PURPOSE The National Cancer Institute of Canada-Clinical Trials Group (NCIC-CTG) conducted a phase II study to assess the efficacy and toxicity of docetaxel as first-line chemotherapy in metastatic breast cancer (MBC). PATIENTS AND METHODS Fifty-one patients with measurable MBC were studied. Three patients were ineligible and were excluded from analysis. The planned dose of docetaxel was 100 mg/m2 intravenously (i.v.) every 3 weeks. Prior adjuvant chemotherapy was allowed if at least 12 months had elapsed from completion of treatment to recurrence. RESULTS The most severe toxicity was granulocytopenia. Ten patients (20.8%) were hospitalized for febrile neutropenia. The protocol was amended to a starting dose of 75 mg/m2 for the last 16 patients. Sixty percent of patients experienced hypersensitivity reactions (HSRs). After two protocol amendments, the use of a premedication regimen of oral dexamethasone and i.v. H1 and H2 blockers prevented significant HSRs. Edema developed in 62% of patients and was cumulative, was present in 50% who received greater than 400 mg/m2, and was not improved by premedication regimens. Following an independent radiology review, 22 partial remissions and four complete responses in 47 assessable patients were confirmed (response rate, 55%; 95% confidence interval [CI], 40% to 69%). The response rate for 15 assessable patients registered at 75 mg/m2 was 40% (95% CI, 16% to 67%); for 32 assessable patients registered at 100 mg/m2, the response rate was 63%, (95% CI, 43% to 78%). CONCLUSION Docetaxel is an active agent in MBC. Its activity as a single agent is comparable to many combination chemotherapy regimens and is not affected by prior adjuvant chemotherapy. Studies are ongoing to improve its therapeutic index and to incorporate docetaxel in combination chemotherapy regimens." @default.
• W1854164300 created "2016-06-24" @default.
• W1854164300 creator A5004859950 @default.
• W1854164300 creator A5040194713 @default.
• W1854164300 creator A5040210551 @default.
• W1854164300 creator A5047113165 @default.
• W1854164300 creator A5052252647 @default.
• W1854164300 creator A5059715152 @default.
• W1854164300 creator A5063914146 @default.
• W1854164300 creator A5067687964 @default.
• W1854164300 creator A5088379395 @default.
• W1854164300 date "1996-02-01" @default.
• W1854164300 modified "2023-10-16" @default.
• W1854164300 title "Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group." @default.
• W1854164300 cites W1537851643 @default.
• W1854164300 cites W1837670228 @default.
• W1854164300 cites W1907962006 @default.
• W1854164300 cites W1919316818 @default.
• W1854164300 cites W1940165440 @default.
• W1854164300 cites W1990328294 @default.
• W1854164300 cites W2036394931 @default.
• W1854164300 cites W2043478531 @default.
• W1854164300 cites W2066550282 @default.
• W1854164300 cites W2077084156 @default.
• W1854164300 cites W2128848742 @default.
• W1854164300 cites W2138550636 @default.
• W1854164300 cites W2227235589 @default.
• W1854164300 cites W2227502215 @default.
• W1854164300 cites W2909208813 @default.
• W1854164300 cites W2409442946 @default.
• W1854164300 doi "https://doi.org/10.1200/jco.1996.14.2.422" @default.
• W1854164300 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8636752" @default.
• W1854164300 hasPublicationYear "1996" @default.
• W1854164300 type Work @default.
• W1854164300 sameAs 1854164300 @default.
• W1854164300 citedByCount "152" @default.
• W1854164300 countsByYear W18541643002012 @default.
• W1854164300 countsByYear W18541643002013 @default.
• W1854164300 countsByYear W18541643002014 @default.
• W1854164300 countsByYear W18541643002015 @default.
• W1854164300 countsByYear W18541643002017 @default.
• W1854164300 countsByYear W18541643002019 @default.
• W1854164300 countsByYear W18541643002020 @default.
• W1854164300 countsByYear W18541643002021 @default.
• W1854164300 countsByYear W18541643002022 @default.
• W1854164300 countsByYear W18541643002023 @default.
• W1854164300 crossrefType "journal-article" @default.
• W1854164300 hasAuthorship W1854164300A5004859950 @default.
• W1854164300 hasAuthorship W1854164300A5040194713 @default.
• W1854164300 hasAuthorship W1854164300A5040210551 @default.
• W1854164300 hasAuthorship W1854164300A5047113165 @default.
• W1854164300 hasAuthorship W1854164300A5052252647 @default.
• W1854164300 hasAuthorship W1854164300A5059715152 @default.
• W1854164300 hasAuthorship W1854164300A5063914146 @default.
• W1854164300 hasAuthorship W1854164300A5067687964 @default.
• W1854164300 hasAuthorship W1854164300A5088379395 @default.
• W1854164300 hasConcept C121608353 @default.
• W1854164300 hasConcept C126322002 @default.
• W1854164300 hasConcept C141071460 @default.
• W1854164300 hasConcept C2775930923 @default.
• W1854164300 hasConcept C2776694085 @default.
• W1854164300 hasConcept C2777063308 @default.
• W1854164300 hasConcept C2777511904 @default.
• W1854164300 hasConcept C2778300832 @default.
• W1854164300 hasConcept C2778850193 @default.
• W1854164300 hasConcept C2781190966 @default.
• W1854164300 hasConcept C2781413609 @default.
• W1854164300 hasConcept C530470458 @default.
• W1854164300 hasConcept C71924100 @default.
• W1854164300 hasConceptScore W1854164300C121608353 @default.
• W1854164300 hasConceptScore W1854164300C126322002 @default.
• W1854164300 hasConceptScore W1854164300C141071460 @default.
• W1854164300 hasConceptScore W1854164300C2775930923 @default.
• W1854164300 hasConceptScore W1854164300C2776694085 @default.
• W1854164300 hasConceptScore W1854164300C2777063308 @default.
• W1854164300 hasConceptScore W1854164300C2777511904 @default.
• W1854164300 hasConceptScore W1854164300C2778300832 @default.
• W1854164300 hasConceptScore W1854164300C2778850193 @default.
• W1854164300 hasConceptScore W1854164300C2781190966 @default.
• W1854164300 hasConceptScore W1854164300C2781413609 @default.
• W1854164300 hasConceptScore W1854164300C530470458 @default.
• W1854164300 hasConceptScore W1854164300C71924100 @default.
• W1854164300 hasIssue "2" @default.
• W1854164300 hasLocation W18541643001 @default.
• W1854164300 hasLocation W18541643002 @default.
• W1854164300 hasOpenAccess W1854164300 @default.
• W1854164300 hasPrimaryLocation W18541643001 @default.
• W1854164300 hasRelatedWork W1531524380 @default.
• W1854164300 hasRelatedWork W1854164300 @default.
• W1854164300 hasRelatedWork W1955744924 @default.
• W1854164300 hasRelatedWork W1968954703 @default.
• W1854164300 hasRelatedWork W2003831525 @default.
• W1854164300 hasRelatedWork W2129979963 @default.
• W1854164300 hasRelatedWork W2149773268 @default.
• W1854164300 hasRelatedWork W2275098507 @default.
• W1854164300 hasRelatedWork W2182487313 @default.
• W1854164300 hasRelatedWork W2409442946 @default.
• W1854164300 hasVolume "14" @default.

• next